News | July 19, 2011

Florbetapir "Imaging to Autopsy" Study Awarded de Leon Prize in Neuroimaging

July 19, 2011 – The study "Use of Florbetapir-PET for Imaging beta-amyloid Pathology," published in the Jan. 19, 2011, issue of the Journal of the American Medical Association, has been selected by the Alzheimer's Association as the winner of the 2011 de Leon Prize in Neuroimaging for the “Best Paper” award in human neuroimaging, in the Senior Scientist category. The award was presented Saturday, July 16, 2011, to Chris Clark, M.D., co-author of the paper and medical director at Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Co., during the Alzheimer's Imaging Consortium (AIC), in Paris, France. The AIC was a preconference to the Alzheimer's Association International Conference 2011 (AAIC 2011), held from July 17-21, 2011.

The paper reported the results of a Phase III "Imaging to Autopsy" study that was designed to determine if florbetapir positron emission tomographic (PET) imaging performed during life predicted the presence or absence of beta-amyloid plaques in the brain at autopsy. The ability to identify and quantify brain beta-amyloid potentially could enable a negative florbetapir-PET scan to rule out amyloid pathology in the brain.

"It is an honor to receive this award as it represents further validation of the importance of the study and recognition of the impact the paper may have on the future of neuroimaging of Alzheimer's disease pathology," said Clark. "Helping to lead this collaborative study was a life-changing event for me and I am pleased to be able to donate the prize earnings back to the Alzheimer's Association to support their efforts."

Florbetapir F18 injection is a molecular PET-imaging agent under investigation for the detection of beta-amyloid plaque in the brains of living patients. Florbetapir F18 was the first beta-amyloid imaging compound to enter multi-center, investigational new drug (IND) clinical studies in the United States. Florbetapir F18 is neither a screener for asymptomatic patients, nor a standalone diagnostic for Alzheimer's disease.

About the de Leon Prize in Neuroimaging

The de Leon Prize in Neuroimaging is presented by the Neuroimaging Professional Interest Area (NPIA) of ISTAART, the Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment.

NPIA awards two prizes annually for the best papers published in any peer-reviewed journal, one in the Senior Scientist category and one in the New Investigator category. Both awards carry unrestricted prizes and are presented during the AIC, a preconference to the AAIC 2011.

The topic of the papers must relate to in-vivo neuroimaging of a neurodegenerative process. The nomination for the "Best Paper" award must be for papers published or in press galley proof, in the period between July 1, 2010 and June 30, 2011.

For more information:



Related Content

ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...